Aarti Drugs ordered by GPCB to cease operations at Gujarat plant
NiveshIQ
NSE: AARTIDRUGS · Pharma
Aarti Drugs Ltd.
₹411.25▲ ₹2.95 (+0.72%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on AARTIDRUGS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Aarti Drugs Ltd.
Aarti Drugs Limited is a leading Indian pharmaceutical company that manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations globally. The company's key revenue drivers include exports, integration of new capacities, and a diverse portfolio of products. Recent developments indicate robust growth and margin gains, driven by these factors. Aarti Drugs competes in a highly competitive pharmaceutical sector, but its strong product portfolio and operational efficiency position it well for growth. The company's Q4 FY26 earnings call transcript highlights its focus on expanding exports and integrating new capacities to drive growth. With a target price of ₹439, analysts expect the company to continue delivering strong f
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,529 Cr +79.90% | ₹2,387 Cr -5.60% | ₹2,565 Cr +7.50% |
| EBITDA Margin | 12.50% | 12.02% | 12.15% |
| Net Profit | ₹172.00 Cr +84.90% | ₹168.00 Cr -2.30% | ₹194.94 Cr +16.00% |
| EPS | ₹18.62 | ₹18.41 | ₹21.36 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Aarti Drugs ordered by GPCB to cease operations at Gujarat plant
Aarti Drugs: ਪ੍ਰਦੂਸ਼ਣ ਕੰਟਰੋਲ ਬੋਰਡ ਨੇ ਗੁਜਰਾਤ ਦੀ ਯੂਨਿਟ ਬੰਦ ਕਰਨ ਦਾ ਹੁਕਮ ਦਿੱਤਾ
🔒
+ 3 more stories about Aarti Drugs Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹720 Cr, PAT ₹55 Cr, EPS ₹6.05, EBITDA margin 13.4%. Growth context: revenue YoY +6.4%, PAT YoY -12.3%, revenue QoQ +19.7%, PAT QoQ +34.8%. Street verdict: inline, revenue surprise -1.6%, PAT surprise +6.8%.
Management commentary highlights key growth drivers, including product launches, approvals, and therapy-mix improvement,...
FY26 (last completed FY): revenue ₹2, 565 Cr, PAT ₹195 Cr, EBITDA margin 12.2%, EPS ₹21.36. Year-on-year: revenue YoY +7...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for AARTIDRUGS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track AARTIDRUGS alongside your other holdings
Unlock full AARTIDRUGS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Aarti Drugs Ltd.?
NiveshIQ detects active intelligence signals for Aarti Drugs Ltd. (AARTIDRUGS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Aarti Drugs Ltd.?
Aarti Drugs Ltd. operates in the Pharma sector with a market capitalisation of ₹375,347.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.